These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

901 related articles for article (PubMed ID: 24041675)

  • 41. Increase of Framingham cardiovascular disease risk score is associated with severity of lower urinary tract symptoms.
    Russo GI; Castelli T; Privitera S; Fragalà E; Favilla V; Reale G; Urzì D; La Vignera S; Condorelli RA; Calogero AE; Cimino S; Morgia G
    BJU Int; 2015 Nov; 116(5):791-6. PubMed ID: 25601421
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Erectile dysfunction (ED) is prevalent, bothersome and underdiagnosed in patients consulting urologists for benign prostatic syndrome (BPS).
    Hoesl CE; Woll EM; Burkart M; Altwein JE
    Eur Urol; 2005 Apr; 47(4):511-7. PubMed ID: 15774251
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effectiveness of tadalafil 5 mg once daily in the treatment of men with lower urinary tract symptoms suggestive to benign prostatic hyperplasia with or without erectile dysfunction: results from naturalistic observational TadaLutsEd study.
    Bechara A; Casabe A; Rodriguez Baigorri G; Cobreros C
    J Sex Med; 2014 Feb; 11(2):498-505. PubMed ID: 24224728
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Correlation of lower urinary tract symptoms with erectile dysfunction in men aged 50 years and above].
    Wang Y; Sun GF; He LJ; Meng J; Wu SL; Xiao YX; Li XS; Na YQ
    Zhonghua Nan Ke Xue; 2008 Jun; 14(6):517-20. PubMed ID: 18649749
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Relationship between Metabolic Syndrome and Predictors for Clinical Benign Prostatic Hyperplasia Progression and International Prostate Symptom Score in Patients with Moderate to Severe Lower Urinary Tract Symptoms.
    Zhao S; Chen C; Chen Z; Xia M; Tang J; Shao S; Yan Y
    Urol J; 2016 Jun; 13(3):2717-26. PubMed ID: 27351328
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Association between ED and LUTS in Japanese motorcyclists.
    Naya Y; Ochiai A; Soh J; Kawauchi A; Miki T
    Int J Impot Res; 2008; 20(6):574-7. PubMed ID: 18923414
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Relationship between Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia and Metabolic Syndrome in Korean Men.
    Park YW; Min SK; Lee JH
    World J Mens Health; 2012 Dec; 30(3):183-8. PubMed ID: 23596610
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.
    Porst H; Kim ED; Casabé AR; Mirone V; Secrest RJ; Xu L; Sundin DP; Viktrup L;
    Eur Urol; 2011 Nov; 60(5):1105-13. PubMed ID: 21871706
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Obstructive lower urinary tract symptoms correlate with erectile dysfunction.
    Elliott SP; Gulati M; Pasta DJ; Spitalny GM; Kane CJ; Yee R; Lue TF
    Urology; 2004 Jun; 63(6):1148-52. PubMed ID: 15183969
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Direct effects of tadalafil on lower urinary tract symptoms versus indirect effects mediated through erectile dysfunction symptom improvement: integrated data analyses from 4 placebo controlled clinical studies.
    Brock GB; McVary KT; Roehrborn CG; Watts S; Ni X; Viktrup L; Wong DG; Donatucci C
    J Urol; 2014 Feb; 191(2):405-11. PubMed ID: 24096120
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term dutasteride therapy in men with benign prostatic hyperplasia alters glucose and lipid profiles and increases severity of erectile dysfunction.
    Traish A; Haider KS; Doros G; Haider A
    Horm Mol Biol Clin Investig; 2017 Jun; 30(3):. PubMed ID: 28632494
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Relationship between Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms and Mean Platelet Volume: The Role of Metabolic Syndrome.
    Zhao S; Tang J; Shao S; Yan Y
    Urol Int; 2016; 96(4):449-58. PubMed ID: 26745140
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Are lower urinary tract symptoms associated with erectile dysfunction in aging males of Taiwan?
    Liu CC; Huang SP; Li WM; Wang CJ; Wu WJ; Chou YH; Huang CH
    Urol Int; 2006; 77(3):251-4. PubMed ID: 17033214
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of the simultaneous administration of mirodenafil and an α-blocker in men with BPH-LUTS: a multicenter open-label prospective study.
    Bang WJ; Oh CY; Yoo C; Cho JS; Yang DY; Lee DH; Lee SH; Chung BH
    Int J Impot Res; 2013; 25(4):149-54. PubMed ID: 23303333
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Association of sexual dysfunction with lower urinary tract symptoms of BPH and BPH medical therapies: results from the BPH Registry.
    Rosen RC; Wei JT; Althof SE; Seftel AD; Miner M; Perelman MA;
    Urology; 2009 Mar; 73(3):562-6. PubMed ID: 19167031
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Association between Benign Prostatic Hyperplasia and Neutrophil-Lymphocyte Ratio, an Indicator of Inflammation and Metabolic Syndrome.
    Ozer K; Horsanali MO; Gorgel SN; Horsanali BO; Ozbek E
    Urol Int; 2017; 98(4):466-471. PubMed ID: 27464069
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Severity of lower urinary tract symptoms reflects different composition of bladder storage dysfunction and bladder outlet obstruction in men with symptomatic benign prostatic hyperplasia.
    Jhang JF; Liao CH; Kuo HC
    Int J Clin Pract; 2014 Jun; 68(6):743-8. PubMed ID: 24471413
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Benign prostatic hyperplasia (BPH) and prostatitis: prevalence of painful ejaculation in men with clinical BPH.
    Nickel JC; Elhilali M; Vallancien G;
    BJU Int; 2005 Mar; 95(4):571-4. PubMed ID: 15705082
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A placebo-controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia.
    Tamimi NA; Mincik I; Haughie S; Lamb J; Crossland A; Ellis P
    BJU Int; 2010 Sep; 106(5):674-80. PubMed ID: 20184577
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [The results of the multicenter prospective comparative study of Androgel in men with endogenous testosterone deficiency and lower urinary tract symptoms, associated with benign prostate hyperplasia (POTOK)].
    Kogan MI; Avadieva NE; Gevorkyan LS; Loginov YA; Metelkin AM; Mitin AA; Patrikeev AA
    Urologiia; 2023 May; (2):32-40. PubMed ID: 37401702
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 46.